PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “GASTROSCOPY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 469 records · Page 26Linked to original sources
PubMed1999

[Propofol for sedation in gastroscopy--a randomized comparison with midazolam].

UNLABELLED: Midazolam, a benzodiazepine with amnestic and sedative effects is the drug of choice for sedation of patients undergoing upper gastrointestinal endoscopy. Propofol, a phenolic derivate, is a short-acting anesthetic producing a more rapid onset sedation amnesia and a shorter recovery than midazolam: In higher doses it acts as hypnotic. The aim of this study was to evaluate both drugs in a prospective randomized trial for sedation of patients undergoing esophagogastroduodenoscopy (EGD). METHODS: 60 patients undergoing EGD were randomized to receive either propofol (n = 30) or midazolam (n = 30). No other analgetic or sedative drugs were used. 3 l oxygen were given routinely by nose. Blood pressure, oxygen saturation (pulse oxymetry) and heart rate was monitored continuously. The sedation quality was determined from the endoscopist and patient separately by use of a scale as either good, fair or insufficient. RESULTS: Changes of the heart rate and oxygen saturation showed no differences in both groups (> 0.05). The blood pressure decreased significant by using propofol (p < 0.01). The sedation quality was good in both groups without significant differences. The recovery time was shorter if propofol was administered (p < 0.01). CONCLUSIONS: Propofol is an alternative drug for sedation in upper endoscopy. It showed same sedation quality as midazolam with the advantage of a short recovery time. Because of a possible decrease of the blood pressure continuous monitoring is recommended.

Adult↗
PubMed2000

[Planned second-look gastroscopy in patients with bleeding ulcer].

Preliminary studies have suggested a beneficial effect of second look endoscopy in patients with bleeding peptic ulcer. We have performed a retrospective survey of 70 patients with bleeding peptic ulcer admitted to our department. Planned second look endoscopy and repeated sclerotherapy was standard care. We found 15 of the 70 patients to rebleed after initial sclerotherapy. Overall success rate of endoscopic therapy was 63/70 patients (90%). The most important factor predicting rebleeding was the occurrence of active bleeding at the initial endoscopy. Compared with an expected rebleeding rate derived from the literature of 20-25 patients, the present study suggests a beneficial effect on rebleeding rate of planned second look endoscopy. Future controlled trials should verify this hypothesis.

Adult↗